Literature DB >> 33778724

Biparametric MRI prior to Radical Radiation Therapy for Prostate Cancer in a Caribbean Population: Implications for Risk Group Stratification and Treatment.

Maria A Gosein1, Dylan Narinesingh1, Shastri Motilal1, Adrian P Ramkissoon1, Cristal M Goetz1, Kristy Sadho1, Murrie D Mosodeen1, Renee Banfield1.   

Abstract

Purpose: To assess risk-group migration and subsequent management change following biparametric MRI using a risk-stratified approach in a group of Caribbean men with prostate adenocarcinoma being offered external beam radiation therapy (EBRT). Materials and
Methods: This retrospective study assessed the biparametric MRI findings in men who opted for EBRT from January 2018 to June 2019 (n = 79; mean age, 67.9 years ± 6.2 [standard deviation]). Serum prostate-specific antigen level, digital rectal examination findings, histologic grade group (GG) from transrectal US-guided biopsy, prior androgen deprivation therapy (ADT), and any prior CT results were used to stratify patients into low-, intermediate-, and high-risk groups, according to the National Comprehensive Cancer Network risk categories. Risk-group stratification prior to MRI separated patients into low- (seven of 79 [8.9%]), intermediate- (36 of 79 [45.6%]) and high-risk (36 of 79 [45.6%]) groups. Following MRI, any risk group (low, intermediate, high, nodal involvement, and metastatic disease) or oncologic management changes were recorded. Multivariable binary logistic regression analyses were used to assess predictor of upgrade status, with adjustment for demographic covariates jointly.
Results: Following MRI, 30 of 79 (38.0%) patients had risk-group upshifts compared with their original assessment. Patients were recategorized into low risk (one of 79, 1.3%), intermediate risk (19 of 79, 24.1%), high risk (51 of 79, 64.6%), nodal involvement (one of 79, 1.3%), and metastatic disease (seven of 79, 8.9%). From the original groupings, there were six of seven (85.7%) from the low group, 18 of 36 (50.0%) from the intermediate group, and six of 36 (16.7%) from the high group that had risk group upward shifts. There was no association with GG: GG2 versus GG1, P = .53; GG3 versus GG1, P = .98; or prior ADT (P = .37) and the adjusted odds of risk-group upshifts. MRI findings resulted in treatment plan modification for 39 of 79 (49.4%) men overall.
Conclusion: Prostate MRI should be considered for patients in high-risk populations prior to EBRT because upstaging from MR image assessment may have implications for modification of treatment.Keywords: MR-Imaging, Prostate, Radiation Therapy© RSNA, 2020See the commentary by Davenport and Shankar in this issue. 2020 by the Radiological Society of North America, Inc.

Entities:  

Year:  2020        PMID: 33778724      PMCID: PMC7983799          DOI: 10.1148/rycan.2020200007

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN: 2638-616X


  27 in total

1.  Endorectal MRI for risk classification of localized prostate cancer: Radiographic findings and influence on treatment decisions.

Authors:  Stanley L Liauw; Lauren M Kropp; Robert T Dess; Aytekin Oto
Journal:  Urol Oncol       Date:  2016-05-27       Impact factor: 3.498

Review 2.  ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging.

Authors:  Fergus V Coakley; Aytekin Oto; Lauren F Alexander; Brian C Allen; Brian J Davis; Adam T Froemming; Pat F Fulgham; Keyanoosh Hosseinzadeh; Christopher Porter; V Anik Sahni; David M Schuster; Timothy N Showalter; Aradhana M Venkatesan; Sadhna Verma; Carolyn L Wang; Erick M Remer; Steven C Eberhardt
Journal:  J Am Coll Radiol       Date:  2017-05       Impact factor: 5.532

3.  Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy.

Authors:  A S N Jackson; C C Parker; A R Norman; A R Padhani; R A Huddart; A Horwich; J E Husband; D P Dearnaley
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-05       Impact factor: 4.126

Review 4.  Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.

Authors:  MaryBeth B Culp; Isabelle Soerjomataram; Jason A Efstathiou; Freddie Bray; Ahmedin Jemal
Journal:  Eur Urol       Date:  2019-09-05       Impact factor: 20.096

5.  Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance.

Authors:  Yun-Sok Ha; Amirali Salmasi; Michael Karellas; Eric A Singer; Jeong Hyun Kim; Misop Han; Alan W Partin; Wun-Jae Kim; Dong Hyeon Lee; Isaac Yi Kim
Journal:  Urology       Date:  2013-03-07       Impact factor: 2.649

6.  Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study.

Authors:  Fiona M Fennessy; Andriy Fedorov; Mark G Vangel; Robert V Mulkern; Maria Tretiakova; Rosina T Lis; Clare Tempany; Mary-Ellen Taplin
Journal:  Acad Radiol       Date:  2019-12-18       Impact factor: 3.173

7.  Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience.

Authors:  Cedric Panje; Thierry Panje; Paul Martin Putora; Suk-Kyum Kim; Sarah Haile; Daniel M Aebersold; Ludwig Plasswilm
Journal:  Radiat Oncol       Date:  2015-02-22       Impact factor: 3.481

8.  A Clinicopathological Profile of Prostate Cancer in Trinidad and Tobago.

Authors:  Ian Hosein; Rajendra Sukhraj; Lester Goetz; Nastassia Rambarran; Satyendra Persaud
Journal:  Adv Urol       Date:  2016-07-17

Review 9.  Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know.

Authors:  Felipe Couñago; Gemma Sancho; Violeta Catalá; Diana Hernández; Manuel Recio; Sara Montemuiño; Jhonathan Alejandro Hernández; Antonio Maldonado; Elia Del Cerro
Journal:  World J Clin Oncol       Date:  2017-08-10

10.  Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry.

Authors:  Nicholas Bullock; Andrew Simpkin; Sarah Fowler; Murali Varma; Howard Kynaston; Krishna Narahari
Journal:  BMC Urol       Date:  2019-10-17       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.